This week, Marker Therapeutics won a grant from what the company describes as a highly competitive Texas cancer research funding programme. The award brings in $16.2 million without requiring Marker to issue a single new share.
Shares closed 54.71% higher at $1.3200 after the grant was announced, on dollar volume of about $48.5 million across 118,512 trades.
For a clinical-stage company, the structure matters as much as the size. Raising cash by selling stock spreads the same company across more shares, making each existing one worth a smaller piece. A grant requires none of that. Marker gets the money and the share count stays where it is.
The Cancer Prevention and Research Institute of Texas — created by the Texas Legislature and approved by Texas voters in 2007 — received 207 applications in this funding cycle and selected 12 projects, distributing a total of $74.3 million. Applications go through a multi-stage review covering scientific merit, manufacturing feasibility, regulatory strategy and commercial potential. Marker's award will fund the Phase 2 APOLLO study, which will test MT-601 in patients whose large B-cell lymphoma came back after CAR-T cell therapy — a treatment in which a patient's immune cells are genetically reprogrammed to attack cancer. Geoffrey Shouse, D.O., Ph.D., Principal Investigator at City of Hope National Medical Center, says that patients who relapse following CAR-T therapy "continue to face limited treatment options and poor clinical outcomes."
The Phase 1 APOLLO results, reported in August 2025, gave CPRIT something to evaluate. Among 12 patients with non-Hodgkin lymphoma who could be assessed, MT-601 produced a 66% objective response rate and a 50% complete response rate. Some of those responses lasted up to 24 months at the data cutoff. The company says no dose-limiting toxicities were observed across evaluated dose levels.
MT-601 targets six tumour antigens at once and uses cells that have not been genetically modified. Marker says that approach is cheaper to manufacture and carries a cleaner safety profile than engineered alternatives. The company has not disclosed the full cost of the Phase 2 trial, or how far the $16.2 million carries it.
One number worth noting alongside the price move: reported short volume on the session came to 13,570,288 shares, against a free float of 12,913,337 — meaning short-side activity reported on the day exceeded the entire tradeable float.
Updated Phase 1 data, including response durability figures, is expected before year-end, the company says. That release will give investors their next read on whether the Phase 1 results that won the grant hold up with more patients and more time.